Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 35kWORD 16k
11 June 2021
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-000424/2021

The Commission’s main objective is to ensure the speedy delivery of vaccines in line with the advanced purchase agreements (APAs). The Commission has tried to mitigate the difficulties associated with the rapid development of vaccines with advanced funding provided through the APAs, but it cannot anticipate delays if not advised in good time by the companies in question.

The Commission is doing everything in its power to support the rollout of vaccines in Europe, including by increasing the availability of vaccines. BioNTech-Pfizer will accelerate delivery of 60 million additional doses of vaccine in the second quarter of 2021.

The delivery of these doses was originally planned for the fourth and third quarter of 2021.This will bring BioNTech-Pfizer's total vaccine doses to 250 million doses in the second quarter.

In relation to AstraZeneca, the Commission has decided to bring legal proceedings against the company for breach of the APA concluded with the company on 27 August 2020 for the supply of 300 million COVID-19 vaccines by the end of the second quarter of 2021.

The Commission is acting on its own behalf and on behalf of the 27 Member States, which are fully aligned in support of the Commission on the need to ensure timely and effective implementation of the APA concluded with AstraZeneca.

The export transparency and authorisation mechanism requiring that export of vaccines outside the EU are subject to an authorisation by Member States was first introduced on 30 January 2021.

In March 2021, the EU decided to extend the mechanism until the end of June 2021. The mechanism ensures that exports under APAs contracted by third countries are safeguarded to the largest extent feasible where principles of reciprocity and proportionality are met.

Last updated: 14 June 2021Legal notice - Privacy policy